People · Operator
Named in public records as an officer, director or promoter · active 2014–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics, Inc | — | Biotechnology | Growth/Late | $1.2B | $8.4B | 2014 |
| Kallyope, Inc. | — | Biotechnology | Series B | $28.1M | $1.1B | 2015 |
Nancy Thornberry at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nancy Thornberry on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Williams | 1 | 27 |
| Bryan Roberts | 1 | 18 |
| Ed Mathers | 1 | 11 |
| Michael O'Donnell | 1 | 11 |
| Adam Goulburn | 1 | 10 |
| Terry McGuire | 1 | 8 |
| Tim Kutzkey | 1 | 7 |
| PATRICK CONWAY | 1 | 6 |
| Kurt Graves | 1 | 5 |
| Gino Santini | 1 | 5 |
| William Rieflin | 1 | 4 |
| Glen Sato | 1 | 4 |
| Joshua Wolfe | 1 | 4 |
| Kenneth Clark | 1 | 3 |
| Jay Skyler | 1 | 3 |
| John Yee | 1 | 2 |
| Barbara G. McClung | 1 | 2 |
| Jay Smith | 1 | 2 |
| Paul Feldman | 1 | 2 |
| James Niedel | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.